Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Lofton-Day

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Gut|February 15, 2013
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancerTimothy Robert Church, Michael Wandell, Catherine Lofton-Day, et al.
Clinical Colorectal Cancer|April 29, 2018
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal CancerTae Won Kim, Anneli Elme, Joon Oh Park, et al.
Clinical Chemistry|May 2, 2009
Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancerTheo deVos, Reimo Tetzner, Fabian Model, et al.
British Journal of Cancer|October 14, 2016
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancerTae Won Kim, Anneli Elme, Zvonko Kusic, et al.
Molecular Cancer Research : MCR|February 23, 2007
Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of diseaseFabian Model, Neal Osborn, David Ahlquist, et al.
Plos One|November 20, 2008
Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assayRobert Grützmann, Bela Molnar, Christian Pilarsky, et al.
The New England Journal of Medicine|January 6, 2012
TFAP2E-DKK4 and chemoresistance in colorectal cancerMatthias P A Ebert, Marc Tänzer, Benjamin Balluff, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Gut|February 15, 2013
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancerTimothy Robert Church, Michael Wandell, Catherine Lofton-Day, et al.
Clinical Colorectal Cancer|April 29, 2018
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal CancerTae Won Kim, Anneli Elme, Joon Oh Park, et al.
Clinical Chemistry|May 2, 2009
Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancerTheo deVos, Reimo Tetzner, Fabian Model, et al.
British Journal of Cancer|October 14, 2016
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancerTae Won Kim, Anneli Elme, Zvonko Kusic, et al.
Molecular Cancer Research : MCR|February 23, 2007
Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of diseaseFabian Model, Neal Osborn, David Ahlquist, et al.
Plos One|November 20, 2008
Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assayRobert Grützmann, Bela Molnar, Christian Pilarsky, et al.
The New England Journal of Medicine|January 6, 2012
TFAP2E-DKK4 and chemoresistance in colorectal cancerMatthias P A Ebert, Marc Tänzer, Benjamin Balluff, et al.
Pageof 2